Nephros, Inc.
US ˙ NasdaqCM ˙ US6406714005

Introduction

This page provides a comprehensive analysis of the known insider trading history of Andrew Astor. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Andrew Astor has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:NEPH / Nephros, Inc. President, CEO & CFO, Director 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Andrew Astor. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases NEPH / Nephros, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in NEPH / Nephros, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
2021-08-18 NEPH Astor Andrew 2,500 7.7733 2,500 7.7733 19,433 37 9.1000 3,317 17.07
2021-08-17 NEPH Astor Andrew 2,500 7.6687 2,500 7.6687 19,172
2020-11-19 NEPH Astor Andrew 1,000 5.8669 1,000 5.8669 5,867
2020-08-19 NEPH Astor Andrew 950 7.4000 950 7.4000 7,030
2020-05-28 NEPH Astor Andrew 1,000 6.9600 1,000 6.9600 6,960
2020-03-12 NEPH Astor Andrew 1,000 6.7000 1,000 6.7000 6,700
2020-03-05 NEPH Astor Andrew 700 8.4567 700 8.4567 5,920
2019-11-18 NEPH Astor Andrew 750 8.3756 750 8.3756 6,282
2019-08-22 NEPH Astor Andrew 1,500 6.9700 1,500 6.9700 10,455
2019-06-14 NEPH Astor Andrew 35,000 0.6400 3,889 5.7600 22,400
2018-04-10 NEPH Astor Andrew 80,000 0.4500 8,889 4.0500 36,000
2018-03-09 NEPH Astor Andrew 5,000 0.4750 556 4.2750 2,375
2017-12-04 NEPH Astor Andrew 8,333 0.5000 926 4.5000 4,166
2017-12-01 NEPH Astor Andrew 10,000 0.5000 1,111 4.5000 5,000
2017-08-28 NEPH Astor Andrew 6,000 0.2700 667 2.4300 1,620
2017-08-28 NEPH Astor Andrew 4,000 0.2729 444 2.4561 1,092
2017-08-11 NEPH Astor Andrew 20,000 0.2599 2,222 2.3391 5,198
2017-03-17 NEPH Astor Andrew 166,666 18,518

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NEPH / Nephros, Inc. Insider Trades
Insider Sales NEPH / Nephros, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in NEPH / Nephros, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

NEPH / Nephros, Inc. Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Andrew Astor as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2022-03-07 2022-03-05 4 NEPH NEPHROS INC
Warrants (right to buy)
M - Exercise -14,815 0 -100.00
2022-03-07 2022-03-05 4 NEPH NEPHROS INC
Common Stock
M - Exercise 14,815 92,773 19.00 2.70 40,000 250,487
2021-12-16 2021-12-14 4 NEPH NEPHROS INC
Stock Option (right to buy)
A - Award 38,612 38,612
2021-08-18 2021-08-18 4 NEPH NEPHROS INC
Common Stock
P - Purchase 2,500 77,958 3.31 7.77 19,433 605,991
2021-08-18 2021-08-17 4 NEPH NEPHROS INC
Common Stock
P - Purchase 2,500 75,458 3.43 7.67 19,172 578,665
2020-11-19 2020-11-19 4 NEPH NEPHROS INC
Common Stock
P - Purchase 1,000 72,958 1.39 5.87 5,867 428,037
2020-08-26 2020-08-24 4 NEPH NEPHROS INC
Stock Option (right to buy)
A - Award 152,064 152,064
2020-08-19 2020-08-19 4 NEPH NEPHROS INC
Common Stock
P - Purchase 950 71,958 1.34 7.40 7,030 532,489
2020-05-29 2020-05-28 4 NEPH NEPHROS INC
Common Stock
P - Purchase 1,000 71,008 1.43 6.96 6,960 494,216
2020-03-12 2020-03-12 4 NEPH NEPHROS INC
Common Stock
P - Purchase 1,000 70,008 1.45 6.70 6,700 469,054
2020-03-05 2020-03-05 4 NEPH NEPHROS INC
Common Stock
P - Purchase 700 69,008 1.02 8.46 5,920 583,580
2020-02-05 2020-02-01 4 NEPH NEPHROS INC
Stock Option (right to buy)
A - Award 13,958 46,525 42.86
2020-02-05 2020-02-01 4 NEPH NEPHROS INC
Stock Option (right to buy)
A - Award 19,320 64,399 42.86
2019-12-18 2019-12-16 4 NEPH NEPHROS INC
Stock Option (right to buy)
A - Award 20,000 20,000
2019-12-18 2019-12-16 4 NEPH NEPHROS INC
Common Stock
A - Award 6,848 68,308 11.14
2019-11-18 2019-11-18 4 NEPH NEPHROS INC
Common Stock
P - Purchase 750 61,460 1.24 8.38 6,282 514,764
2019-08-22 2019-08-22 4 NEPH NEPHROS INC
Common Stock
P - Purchase 1,500 60,710 2.53 6.97 10,455 423,149
2019-08-13 2019-08-09 4 NEPH NEPHROS INC
Stock Option (right to buy)
A - Award 9,305 32,567 40.00
2019-08-13 2019-08-09 4 NEPH NEPHROS INC
Stock Option (right to buy)
A - Award 12,880 45,079 40.00
2019-06-14 2019-06-14 4 NEPH NEPHROS INC
Common Stock
P - Purchase 35,000 532,903 7.03 0.64 22,400 341,058
2018-12-21 2018-12-19 4 NEPH NEPHROS INC
Stock Option (right to buy)
A - Award 200,000 200,000
2018-12-18 2018-12-14 4 NEPH NEPHROS INC
Common Stock
A - Award 44,111 497,903 9.72
2018-05-14 2018-05-14 4 NEPH NEPHROS INC
Warrants (right to buy)
X - Other -33,333 133,333 -20.00
2018-05-14 2018-05-14 4 NEPH NEPHROS INC
Common Stock
X - Other 33,333 453,792 7.93 0.30 10,000 136,138
2018-04-12 2018-04-10 4 NEPH NEPHROS INC
Common Stock
P - Purchase 80,000 420,459 23.50 0.45 36,000 189,207
2018-03-13 2018-03-09 4 NEPH NEPHROS INC
Common Stock
P - Purchase 5,000 340,459 1.49 0.48 2,375 161,718
2017-12-22 2017-12-20 4 NEPH NEPHROS INC
Stock Option (right to buy)
A - Award 50,000 50,000
2017-12-22 2017-12-20 4 NEPH NEPHROS INC
Common Stock
A - Award 120,417 335,459 56.00
2017-12-05 2017-12-04 4 NEPH NEPHROS INC
Common Stock
P - Purchase 8,333 215,042 4.03 0.50 4,166 107,521
2017-12-05 2017-12-01 4 NEPH NEPHROS INC
Common Stock
P - Purchase 10,000 206,709 5.08 0.50 5,000 103,354
2017-08-28 2017-08-28 4 NEPH NEPHROS INC
Common Stock
P - Purchase 4,000 196,709 2.08 0.27 1,092 53,682
2017-08-28 2017-08-28 4 NEPH NEPHROS INC
Common Stock
P - Purchase 6,000 192,709 3.21 0.27 1,620 52,031
2017-08-28 2017-06-16 4 NEPH NEPHROS INC
Common Stock
L - Other 43 186,709 0.02 0.26 11 49,478
2017-08-11 2017-08-11 4 NEPH NEPHROS INC
Common Stock
P - Purchase 20,000 186,666 12.00 0.26 5,198 48,514
2017-05-15 2017-05-01 4/A NEPH NEPHROS INC
Stock Option (right to buy)
A - Award 209,355 209,355
2017-05-02 2017-05-01 4 NEPH NEPHROS INC
Stock Option (right to buy)
A - Award 209,355 209,355
2017-03-21 2017-03-17 4 NEPH NEPHROS INC
Warrants (right to buy)
P - Purchase 166,666 166,666
2017-03-21 2017-03-17 4 NEPH NEPHROS INC
Common Stock
P - Purchase 166,666 166,666
2017-02-15 2017-02-13 4 NEPH NEPHROS INC
Stock Option (right to buy)
A - Award 289,785 289,785
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)